Аногенитальные кондиломы: современные представления о патогенезе и подходы к терапии

1. de Villiers EM et al. Classification of papillomaviruses.
Virology 2004; 324: 17.
2. Longworth MS, Laimins LA. Pathogenesis of
human рapillomaviruses in differentiating epithelia.
Microbiol Mol Biol Rev 2004; 68: 362.
3. Doorbar J. The papillomavirus life cycle. J Clin
Virol 2005; 32 (Suppl. 1): S7.
4. Peh WL, Doorbar J. Detection of papillomavirus
proteins and DNA in paraffin-embedded tissue sections.
Methods Mol Med 2005; 119: 49.
5. Munoz N et al. Epidemiologic classification of
human papillomavirus types associated with cervical
cancer. N Engl J Med 2003; 348: 518.
6. Wang Q et al. Functional analysis of the human
papillomavirus type 16 E1-E4 protein provides a
mechanism for in vivo and in vitro keratin filament
reorganization. J Virol 2004; 78: 821.
7. Goncalves MA, Donadi EA. Immune cellular
response to HPV: current concepts. Braz J Infect Dis
2004; 8: 1–9.
8. Astori G et al. Human papillomaviruses are commonly
found in normal skin of immunocompetent
hosts. J Invest Dermatol 1998; 110: 752.
9. Myhre AK et al. Anogenital human papillomavirus
in non-abused preschool children. Acta Paediatr
2003; 92: 1445.
10. Wiatrak BJ et al. Recurrent respiratory papillomatosis:
a longitudinal study comparing severity
associated with human papilloma viral types 6 and
11 and other risk factors in a large pediatric population.
Laryngoscope 2004; 114 (11 Pt 2 Suppl. 104): 1.
11. Kimberlin DW. Current status of antiviral
therapy for juvenile-onset recurrent respiratory papillomatosis.
Antiviral Res 2004; 63: 141–51.
12. Wolff K, Goldsmith LA, Katz SI. Fitzpatrick's
Dermatology in General Medicine, 7th Edition,
McGraw Hill. 2008.
13. Castellsagúe X, Mũnoz N. Chapter 3: Cofactors
in human papillomavirus carcinogenesis – role of parity,
oral contraceptives, and tobacco smoking. J Nat
Cancer Instit Monogr 2003; 31: 20–8.
14. Smith JS, Herrero R, Bosetti C et al. Herpes
simplex virus-2 as a human papillomavirus cofactor
in the etiology of invasive cervical cancer. J Nat Cancer
Instit 2002; 94 (21): 1604–13.
15. FUTURE II Study Group. Quadrivalent vaccine
against human papillomavirus to prevent high-grade
cervical lesions. N Engl J Med 2007; 356 (19): 1915–27.
16. Garland SM, Hernandez-Avila M, Wheeler CM
et al. Quadrivalent vaccine against human papillomavirus
to prevent anogenital diseases. N Engl J Med
2007; 356 (19): 1928–43.
17. Villa LL et al. Prophylactic quadrivalent human
papillomavirus (types 6, 11, 16, and 18) L1 virus-like
particle vaccine in young women: A randomised doubleblind
placebo-controlled multicentre phase II efficacy
trial. Lancet Oncol 2005; 6: 271.
18. Fox PA, Tung MY. Human papillomavirus:
burden of illness and treatment cost considerations.
Am J Clin Dermatol 2005; 6 (6): 365–81.

А.В.Миченко, А.Н.Львов
Первый МГМУ им. И.М.Сеченова